 BOSTON, April 01, 2021 GLOBE NEWSWIRE -- Paratek Pharmaceuticals, Inc. Nasdaq: PRTK, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on March 31, 2021, the Company granted stock options and restricted stock units to three new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Companys board of directors on June 15, 2017, under Rule 5635c4 of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company. The stock options are to acquire, in the aggregate, 1,200 shares of the Companys common stock at a per share exercise price of 7.06, the closing sales price on March 31, 2021, and shall vest over a four-year vesting period, under which 25 of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employees continuous service. The restricted stock units are to acquire, in the aggregate, 13,800 shares of the Companys common stock and shall vest upon the conclusion of a 36-month vesting period, under which one hundred percent 100 of the restricted stock units will vest after 36 months of employment, subject to the employees continuous service. The stock options and restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement and restricted stock unit award agreement covering each grant. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use. The companys lead commercial product, NUZYRA omadacycline, is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA sarecycline, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC, or Almirall. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from the Biomedical Advanced Research and Development Authority BARDA to support the development of NUZYRA for the treatment of pulmonary anthrax. For more information, visit or follow ParatekPharma on Twitter. About NUZYRANUZYRA omadacycline is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia CABP and acute bacterial skin and skin structure infections ABSSSI. A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains. Please see full Prescribing Information for NUZYRA at CONTACT:Investor and Media Relations: Ben Strain 617-807-6688 